Amber Specialty Pharmacy to Dispense ADUHELM™ (aducanumab) for the Treatment of Alzheimer’s
Alzheimer’s disease is a progressive neurological illness that impairs thinking and independence of millions of people worldwide. According to the Alzheimer’s Association, an estimated 6.2 million Americans, and more than 40 million people worldwide, are living with Alzheimer’s disease and related dementias. It is the 3rd leading cause of mortality in people over 65, behind cancer and heart disease. While Alzheimer’s disease is usually diagnosed in people 65 and older, it starts earlier with subtle neurological changes occurring years or even decades before symptoms appear.
Licensed in all 50 states, plus Puerto Rico, Amber Specialty Pharmacy's best-in-class service model will support memory and dementia specialists and patients throughout the country.
“We are committed to partnering with prescribers to support caregivers, families and patients as they navigate a devastating diagnosis like Alzheimer’s,” said Kristin Williams, president of Amber Specialty Pharmacy and Chief Health Officer of Hy-Vee, Inc. “The ability to offer this new treatment option is something of which we are very proud.”
About Amber Specialty Pharmacy
Amber Specialty Pharmacy is a pioneer and leader in the specialty pharmacy industry with over 23 years of experience providing specialized care for persons with chronic, complex medical conditions. Amber Specialty Pharmacy has built an outstanding reputation by providing personalized support and quality clinical care to patients and families. This comprehensive care approach supports the medical, emotional, financial and administrative needs of patients throughout the United States. Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC). Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with additional 20 locations throughout the United States.
Source: Amber Specialty Pharmacy